Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.
1. An enema product configured for transporting to a remote facility, the enema product comprising a container and a pharmaceutical composition within the container, the pharmaceutical composition formulated for enema delivery directly from the container, wherein the container comprises an oxygen-resistant material, and wherein the pharmaceutical composition comprises saline, a cryoprotectant, and the substantially entire microbiota of a stool sample, wherein the pharmaceutical composition is free of rough particulate matter of the stool sample, wherein the substantially entire microbiota is in an amount effective for treating a C. difficile infection.
2. The enema product of claim 1 , wherein the cryoprotectant stabilizer comprises polyethylene glycol.
3. The enema product of claim 1 , wherein the cryoprotectant comprises trehalose.
4. The enema product of claim 1 , wherein the saline comprises sodium chloride.
5. The enema product of claim 1 , wherein the container comprises plastic.
6. The enema product of claim 1 , wherein the container is a bag.
7. The enema product of claim 1 , wherein the enema product comprises flexible tubing for delivery of the pharmaceutical composition to a subject.
8. The enema product of claim 1 , wherein the stool sample is derived from a healthy human donor.
9. The enema product of claim 1 , wherein the stool sample has a weight of 50 grams.
10. The enema product of claim 1 , wherein the pharmaceutical composition frozen.
11. An enema delivery system comprising a bag, flexible tubing, and a pharmaceutical composition within the bag, wherein the pharmaceutical composition is formulated for enema delivery directly from the bag via the flexible tubing, wherein the pharmaceutical composition comprises saline, polyethylene glycol and the substantially entire microbiota of a stool sample separated from rough particulate matter of the stool sample, wherein the bag comprises an oxygen-resistant material, and wherein the pharmaceutical composition is in an amount effective for treating recurrence of C. difficile infection.
12. The enema product of claim 11 , wherein the rough particulate matter comprises fiber.
13. The enema product of claim 11 , wherein the substantially entire microbiota is free of rough particulate matter of the stool sample.
14. A method comprising: incorporating into a container a pharmaceutical composition comprising a saline, a cryoprotectant, and the substantially entire microbiota of a stool sample to produce an enema product of claim 1 ; freezing the enema product and shipping the enema product to a remote facility.
15. The method of claim 14 , wherein the method further comprises sending the enema product to a remote facility for infusion of the microbiota into the rectum of a subject.
16. The method of claim 4 , wherein the stabilizer comprises a cryoprotectant.
17. The method of claim 16 , wherein the cryoprotectant comprises polyethylene glycol.
18. The method of claim 14 , wherein the container is a bag.
19. The method of claim 14 , further comprising receiving the stool sample, wherein the stool sample is derived from a healthy human donor.